Melanotan-I (Afamelanotide)

Linear 13-aa α-MSH analog and the FDA-approved cousin of MTII. Designed at the University of Arizona alongside MTII in the 1980s and developed (after MTII was abandoned) by Clinuvel Pharmaceuticals into Scenesse, a 16 mg subcutaneous controlled-release implant approved 2019 for the orphan disease erythropoietic protoporphyria. MC1R-preferential — drives eumelanin synthesis with substantially less MC4R/MC3R/MC5R hit than MTII, which means much less nausea, no priapism, no chronic appetite suppression. Two distinct compounds in practice: the regulated implant (60-day controlled release, $40-50K/year, restricted distribution to EPP centers only) and the gray-market injectable peptide (250-500 mcg subQ daily/maintenance pattern, $30-50/10 mg vial, vendor-quality variable). Mechanistically the cleanest cosmetic-tanning melanocortin tool available, but the long-term melanoma question remains unanswered at peptide-community doses, and the regulatory approval doesn't map onto cosmetic use. For Dylan: WATCH-LIST. Nordic-ancestry fair-skin + minimal-sun-exposure + outdoor-MMA-on-occasion phenotype is the archetype where MTI's photoprotection rationale has surface plausibility, and the cleaner side-effect profile vs. MTII removes most of the dealbreakers in the sister compound. But the dermatologic-baseline-and-monitoring commitment isn't free, melanoma risk at peptide-community doses is unstudied, and Dylan's cosmetic-tanning interest isn't established as a stated priority. Revisit after 23andMe (MC1R genotype) and bloodwork (June 2026).

Plain English: Melanotan-I is α-MSH — the body's "make more pigment" hormone — with two surgical tweaks that make it last hours instead of minutes and lock the active conformation into the right shape. Unlike MTII (its cyclic, more-aggressive cousin), MTI is a linear peptide that hits MC1R on skin melanocytes preferentially. The result is the same tanning signal, with much less of the side-effect noise that comes from MTII hitting MC4R in your hypothalamus (nausea, appetite suppression, erections) and MC3R (sexual motivation) and MC5R (sebaceous overdrive). Same goal — eumelanin synthesis for dark, photoprotective pigment. Cleaner channel.

Detailed mechanism:

1. Structure. Linear tridecapeptide: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. Two key modifications from native α-MSH: norleucine (Nle) substituted for methionine at position 4 (resists oxidation), and D-phenylalanine substituted for L-phenylalanine at position 7 (resists peptidase cleavage + locks bioactive turn). This is the original "NDP-α-MSH" (4-Norleucine, 7-D-Phe-α-MSH) designed by Sawyer, Hruby, Hadley, and colleagues at the University of Arizona in the early 1980s, predating MTII. Result: a peptide ~10-1000× more potent than native α-MSH (depending on assay) and with hours-scale plasma half-life vs. native α-MSH's minutes.

2. Receptor profile. Agonist at MC1R, MC3R, MC4R, MC5R; negligible MC2R activity. Critical distinction from MTII: MTI is MC1R-preferential — its linear structure favors MC1R binding pockets more than the cyclic MTII does. The clinical translation is substantially reduced central (MC4R-driven nausea, satiety, erection) and exocrine (MC5R sebaceous, immune) effects at therapeutic doses. This is why Scenesse can be implanted at 16 mg for 60-day controlled release without producing the priapism, severe nausea, or appetite suppression that killed MTII as a cosmetic candidate. The selectivity is not absolute — at high doses MTI still produces some nausea and some yawning — but the dose-response curves for MC1R vs. MC4R are far enough apart to be clinically meaningful.

3. MC1R → tanning. Same downstream cascade as MTII. Melanocyte MC1R activation → Gαs coupling → adenylyl cyclase → cAMP rise → PKA → CREB phosphorylation → MITF transcription factor upregulation → tyrosinase / TRP1 / TRP2 / DCT enzyme expression → pheomelanin → eumelanin shift in pigment production. Same UV requirement caveat as MTII: MTI drives the capacity for melanogenesis. UV exposure (sunlight or tanning bed) is still the canonical trigger that recruits melanocytes to actually produce and transfer pigment to keratinocytes. Without UV, MTI produces only modest pigmentation deepening of existing pigmented areas. In the Scenesse EPP indication, UV exposure is the medical problem (EPP patients have phototoxic reactions to sunlight) — so Scenesse is dosed to allow normal sun exposure that EPP patients would otherwise need to avoid.

4. MC4R/MC3R → libido + satiety (much less than MTII). Present but attenuated. Some users report mild appetite suppression on first dose; spontaneous erections are uncommon (vs. ubiquitous with MTII). Scenesse trial data show some mild GI symptoms in early loading but no priapism cases.

5. MC5R → exocrine + immune (much less than MTII). Less acne / sebaceous activation reported in trial data.

6. Photoprotective mechanism beyond tanning. Eumelanin in keratinocyte supranuclear caps is photoprotective — it absorbs UV photons and dissipates the energy thermally rather than producing reactive oxygen species or pyrimidine dimers in DNA. Increased eumelanin density (the goal of MTI dosing) provides ~SPF 2-4 of additional baseline photoprotection in lighter skin types — modest but real. This is the basis of the EPP indication: EPP patients suffer photosensitivity from accumulated protoporphyrin IX in skin; eumelanin upregulation reduces UV-induced ROS generation and tissue damage.

7. Pharmacokinetics — Scenesse implant vs. injectable.

   • Scenesse implant: 16 mg lyophilized rod, subcutaneous (suprailiac) implantation by clinician. Releases peptide over ~2 days (loading) then declines over ~60 days. Designed for sustained low-level MC1R activation. Plasma levels peak day 1-2, decline by day 5-10, with continuing skin pigmentation effect 60+ days post-implant.
   • Gray-market injectable: SC injection 250-500 mcg, plasma t½ ~hours (much shorter than implant exposure), repeated daily during loading then 2-3×/week maintenance. Pharmacokinetically distinct — bolus exposure with peaks and troughs vs. controlled release. Side effect profile during peak (nausea, flushing) is more pronounced in injectable use than implant use because of the higher Cmax.

8. Vitamin D synthesis interaction (contested claim). Some peptide-community sources claim MTI "preserves UV-induced vitamin D synthesis pathways while still tanning," distinguishing it from sunscreen-based photoprotection. The honest mechanism: eumelanin in skin reduces UVB transmission, modestly reducing 7-dehydrocholesterol → previtamin D3 conversion at a given UV dose. Darker-skinned individuals do produce less vitamin D per unit UV exposure than fair-skinned individuals, all else equal. So MTI-induced eumelanin upregulation will, mechanically, slightly reduce the rate of vitamin D synthesis per minute of sun exposure. The "preserves D synthesis" claim is misleading. Practical implication for Dylan: continue 5000 IU D3 (V4 stack) regardless. Do not assume MTI substitutes for D3 supplementation.